Mid Atlantic Financial Management’s BioMarin Pharmaceuticals BMRN Stock Holding History

Mid Atlantic Financial Management’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q3	–	Sell	-2,590	Closed	-$216K	–	914
2021 Q2	$216K	Sell	2,590 -147	-5%	-$11.7K	0.01%	809
2021 Q1	$207K	Buy	2,737 +19	+0.7%	+$1.55K	0.02%	762
2020 Q4	$238K	Sell	2,718 -153	-5%	-$12.1K	0.02%	662
2020 Q3	$216K	Sell	2,871 -62	-2%	-$6.27K	0.02%	630
2020 Q2	$362K	Hold	2,933	–	–	0.03%	428
2020 Q1	$248K	Buy	2,933 +64	+2%	+$5.51K	0.03%	503
2019 Q4	$243K	Buy	+2,869	New	+$217K	0.02%	587
2019 Q3	–	Sell	-2,433	Closed	-$208K	–	706
2019 Q2	$208K	Sell	2,433 -24	-1%	-$2.05K	0.02%	631
2019 Q1	$218K	Sell	2,457 -118	-5%	-$10.9K	0.02%	605
2018 Q4	$219K	Buy	+2,575	New	+$245K	0.03%	560

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Mid Atlantic Financial Management's BMRN Position: Q3 2021 in Review

Mid Atlantic Financial Management sold out of BioMarin Pharmaceuticals (BMRN) in Q3 2021, closing a stake of 2,590 shares — an estimated $216K sold.

Mid Atlantic Financial Management first reported a position in BMRN in Q4 2018 and held it in 10 quarters. The position peaked at $362K in Q2 2020. 512 funds tracked by Wall St. Rank hold BMRN as of Q3 2021.

Mid Atlantic Financial Management reported no remaining BioMarin Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
Mid Atlantic Financial Management sold 2,590 BioMarin Pharmaceuticals shares in Q3 2021, an estimated $216K.
Mid Atlantic Financial Management first reported a position in BioMarin Pharmaceuticals in Q4 2018 and held it in 10 quarters.
Mid Atlantic Financial Management's BioMarin Pharmaceuticals position peaked at $362K in Q2 2020.
512 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q3 2021.

Based on Mid Atlantic Financial Management's 13F filing for Q3 2021, filed 12 Nov 2021.